查看文章

Nanomedicine is an emerging field that has caught the interest of many medical scientists and chemists due to its unique characteristics that open the door wide for several unique applications that might lead to solving many problems that were found difficult to tackle in medicine. Nanomedicine has opened a new category of medicines called nanomedicines where the medicine is reduced to the nanoscale size, hoping to enhance its physicochemical properties. The chapter summarizes the nanomedicines that have been approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) and the nanomedicines whose clinical trials based on previously published review articles by Anselmo and Mitragotri are ongoing [1, 2]. To gain insight to current trends in nanomedicine research and the most successful types of nanomedicines in the market, the approved nanomedicines are presented in Figure 1. The number of approved nanomedicine products is 29 till 2019 [1]. Liposomes represented 44.8%(13 products). Inorganic nanoparticles ranked second with 41.4%(12 products). Other nanoparticles (polymeric and protein) have only 4 products (13.8%). These findings are very interesting as liposomes are one of the oldest nanomedicines. This opens an argument about the challenges in nanomedicine translation as a new platform requires further investigations to prove its activity and safety. On the other hand, cancer nanotherapeutics is ranked first with 10 products in the market, followed by iron-replacement therapies with 8 products. Also, it is worth to mention that imaging agents (six marketed products) are ranked in third …